Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 9/20 | 0.45 |
| ▸ | EDNRA | P25101 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 3/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4768277 | 0.94 | STING1 (0.43) | STING1EDNRAARACHE | |
| SCHEMBL5224507 | 0.83 | NMT1 (0.45) | STING1ACHE | |
| SCHEMBL4766147 | 0.79 | EDNRA (0.45) | EDNRAL3MBTL1 | |
| SCHEMBL4768131 | 0.79 | STING1 (0.43) | STING1EDNRAL3MBTL1GPR35LCK | |
| SCHEMBL4762820 | 0.78 | STING1 (0.43) | STING1EDNRAL3MBTL1GPR35 | |
| SCHEMBL5767040 | 0.78 | PIK3CD (0.39) | STING1L3MBTL1 | |
| SCHEMBL4770363 | 0.77 | EDNRA (0.45) | STING1EDNRAL3MBTL1ACHE | |
| SCHEMBL6020724 | 0.77 | STING1 (0.46) | STING1L3MBTL1ACHE | |
| SCHEMBL6021022 | 0.77 | STING1 (0.49) | STING1L3MBTL1ACHE | |
| SCHEMBL6020606 | 0.75 | STING1 (0.44) | STING1L3MBTL1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287469-A1 | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation | DIACOVO THOMAS G | 2008-11-20 | — | — | US | claimed |
| EP-1885356-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2008-02-13 | — | — | EP | claimed |
| WO-2006089106-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2006-08-24 | — | — | WO | claimed |
| US-20080287469-A1 | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation | DIACOVO THOMAS G | 2008-11-20 | — | — | US | disclosed |
| EP-1636212-B1 | CYCLOALKYLSULFANYL SUBSTITUTED BENZO¬B|THIOPHENES AS THERAPEUTIC AGENTS | WARNER LAMBERT CO (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1636212-A1 | CYCLOALKYLSULFANYL SUBSTITUTED BENZO[B]THIOPHENES AS THERAPEUTIC AGENTS | Warner-Lambert Company LLC (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004108714-A1 | CYCLOALKYLSULFANYL SUBSTITUTED BENZO[B]THIOPHENES AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040248954-A1 | Cycloalkylsulfanyl substituted benzo[b]thiophenes as therapeutic agents | GOGLIOTTI ROCCO DEAN (US) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248954-A1 | Cycloalkylsulfanyl substituted benzo[b]thiophenes as therapeutic agents | MALT1, BPNT1, CYP1B1 | STING1 2995/4885EDNRA 2852/4885AR 1963/4885 |
| US-20080287469-A1 | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation | PI4KB, PIK3CA, PI4KA | STING1 915/4885EDNRA 1595/4885AR 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.